Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades
Stock Jumps as Outlook Brightens Gilead’s share price has been on a tear in recent weeks, reaching new highs for 2025. By mid-day October 17, GILD was up about 4.7% to roughly $123 per share benzinga.com. Year-to-date, the stock has rallied nearly 47%, adding tens of billions to Gilead’s market value stockanalysis.com. This far outpaces the single-digit gain of the Nasdaq Biotechnology Index over the same period stockanalysis.com invesco.com. Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects. Notably, Gilead’s Q2 results in August beat expectations and prompted management to raise